Incorporation of pazopanib in maintenance therapy of ovarian cancer
Purpose Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
CF Xu, T Johnson, X Wang, C Carpenter… - Clinical Cancer …, 2016 - AACR
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-
tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib …
tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib …
Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian study
Objective The recent phase 3 trial AGO-OVAR16 demonstrated that pazopanib maintenance
improved median progression-free survival in patients with ovarian cancer whose disease …
improved median progression-free survival in patients with ovarian cancer whose disease …
Protein-coding genes as molecular markers for ecologically distinct populations: the case of two Bacillus species.
T Palys, E Berger, I Mitrica… - … of Systematic and …, 2000 - microbiologyresearch.org
Bacillus globisporus and Bacillus psychrophilus are one among many pairs of ecologically
distinct taxa that are distinguished by very few nucleotide differences in 16S rRNA gene …
distinct taxa that are distinguished by very few nucleotide differences in 16S rRNA gene …
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial
Background Analysis of progression-free survival (PFS) as the primary endpoint in
advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer (AEOC) trials may …
advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer (AEOC) trials may …
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
EMJ van Brummelen, E Levchenko, M Dómine… - Investigational new …, 2020 - Springer
Summary Background Fibroblast growth factors (FGFs) have a fundamental role in cancer.
Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while …
Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while …
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
D Morgensztern, N Karaseva, E Felip, I Delgado… - Lung Cancer, 2019 - Elsevier
Abstract Objectives GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand
trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and …
trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and …
Pazopanib (Paz) monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, Fallopian tube, or primary peritoneal …
R Zang, L Wu, J Zhu, B Kong, BG Kim, Y Yao, R Yin… - 2013 - ascopubs.org
5512 Background: Paz, an oral multikinase inhibitor of VEGF, PDGF and c-Kit has showed
activity in advanced ovarian cancer. This study evaluated paz as maintenance therapy in …
activity in advanced ovarian cancer. This study evaluated paz as maintenance therapy in …
Abstract A6: Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: Results of two phase I studies
H Burris III, A du Bois, A Dowlati, S Gainer… - Molecular Cancer …, 2009 - AACR
Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor targeting VEGFR, PDGFR,
and c‐Kit with w/a recommended dose of 800 mg/day as monotherapy. Preclinical activity …
and c‐Kit with w/a recommended dose of 800 mg/day as monotherapy. Preclinical activity …
Multicenter, nonrandomized, open-label phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)
JMT Perez, E van Brummelen… - Annals of …, 2017 - annalsofoncology.org
Background: Fibroblast growth factor (FGF) signaling has a fundamental role in cancer
development and tumor maintenance. FP-1039/GSK3052230 is a soluble decoy receptor …
development and tumor maintenance. FP-1039/GSK3052230 is a soluble decoy receptor …